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Serum Levels of Rubella Virus Antibodies Indicating Immunity: Response to
Vaccination of Subjects with Low or Undetectable Antibody Concentrations
Lukas Matter, Karen Kogelschatz, and Daniel Germann Institute for Medical Microbiology, University of Bern, Switzerland
To define the concentration of anti–rubella virus (RV) antibodies discriminating nonimmune
from immune persons and to characterize immune responses to rubella vaccination, serologic studies
were performed after rubella vaccination in persons with low or undetectable antibody concentra-
tions. Thirty-six subjects with primary immune responses had prevaccination anti-RV IgG concen-
trations õ15 IU/mL by ELISA and negative results by radial hemolysis. Eighty-three subjects with
secondary immune responses had mean IgG increases of 9 IU/mL within 2 weeks. Eight of them
had initial IgG levels õ15 IU/mL, and 2 were negative by radial hemolysis. Both groups attained
similar antibody levels after 1–3 months. Secondary immune responses to rubella vaccination were
delayed by ú2 weeks and thus resembled the time course of primary immunization, but IgM
responses and IgG avidity were distinct between subjects with primary or secondary immune re-
sponses. Thresholds for immunity õ15 IU/mL entail the risk of withholding rubella vaccination
from susceptible persons.
Prevention of the congenital rubella syndrome rests on the secondary immune responses [8, 11, 12, 28–30]. However,
rubella revaccination may induce only weak or transient re-efficient implementation of childhood vaccination programs
and on the detection and vaccination of women of childbearing sponses [11, 21, 22]. The question ‘‘are many women immu-
nized against rubella unnecessarily?’’ [12] remains unan-age who are susceptible to rubella [1]. Definition of a cutoff
level for anti–rubella virus (RV) antibodies that reliably indi- swered, particularly for the allegedly more sensitive modern
tests. We therefore studied the immune response in personscates previous exposure and immunization by RV, and thereby
presumably immunity in terms of protection from intrauterine who had received rubella vaccine because of low or undetect-
able anti-RV antibodies, in order to establish the cutoff for aninfection, is therefore important [1–3]. Hemagglutination inhi-
bition and radial hemolysis are time-honored techniques with automated IgG ELISA and to compare its performance with
radial hemolysis as well as to characterize the kinetics anddisadvantages such as nonspecific inhibition by serum compo-
nents other than antibodies [4–6] and difficulties in providing vigor of primary and secondary responses.
suitable reagents. They are increasingly being replaced by vari-
ous ELISAs or latex agglutination assays [1, 7–10] that may
Materials and Methods
detect lower concentrations of anti-RV IgG antibodies than do
Study population. Between 30 July 1992 and 1 Novemberolder techniques [7]. This creates problems for standardization
1995, consecutive testing of 5060 subjects for anti-RV IgG re-and uncertainties as to the antibody levels that indicate immu-
vealed 1015 with low or undetectable levels of IgG (i.e., õ40 IU/nity [4, 5, 9–14]. The estimation of the persistence of anti-RV
mL). Of these, 501 were offered serologic testing if their physiciansantibodies [15–19] and the surveillance of rubella vaccination
considered rubella vaccination to be indicated and if they werestrategies by age-stratified seroprevalence studies [20] also de-
negative for anti-RV IgM. Determination of anti-RV IgG was
pend on the reliability of the techniques in detecting susceptible
offered at 1 week and 1–2 months after vaccination. We obtained
persons in need of vaccination. information on rubella vaccination and serum samples from a total
The response to vaccination may give insight into the immu- of 165 subjects (only 4 were men). Of the subjects, 139 had been
nologic experience of a person irrespective of the current serum tested in a pregnancy screening program, 19 were health care
level of antibodies [21–24]. The production of high-avidity workers, and 7 were tested for other reasons. One hundred forty-
seven first samples were taken within a mean of 7 days (SD, 2.6)IgG within several days after reexposure to RV [25–27] and
and 119 samples within 37 days (SD, 9) after vaccination. A thirdthe lack of an IgM response are the expected hallmarks of
sample was obtained from 11 subjects after 56–545 days. The
group without follow-up contained 282 women and 54 men. The
median age and anti-RV IgG concentration were similar in vacci-
nated women before vaccination and in women without follow-up
Received 16 July 1996; revised 25 October 1996.
(28.9 vs. 28.7 years and 20 IU/mL in both groups; P ú .05,Presented in part: 34th annual meeting, Infectious Diseases Society of
Mann-Whitney U test). The distribution of IgG values was alsoAmerica, New Orleans, 19 September 1996 (abstract 69).
This study was approved unanimously by the Ethical Commission of the comparable in women who were not included in the study and
Medical Faculty, University of Bern (73/96). those who were followed up, with about one-third having õ10
Reprints or correspondence: Dr. L. Matter, Institute for Medical Microbiol-
IU/mL in both groups. About two-thirds of the men had valuesogy, University of Bern, Friedbühlstrasse 51, CH-3010 Bern, Switzerland.
õ10 IU/mL, but most of them were not available for follow-up.
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Methods. Serum was separated from blood cells within 2–14q 1997 by The University of Chicago. All rights reserved.
0022–1899/97/7504–0002$01.00 h after venipuncture and tested for anti-RV IgG. The serum samples
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were maintained at 2–87C for 2–10 days, until they were aliquoted a primary immune response to rubella vaccination character-
and kept frozen at 0207C for further testing. Anti-RV IgG concen- ized by low anti-RV IgG avidity (figure 2A) and positive anti-
trations were measured by ELISA. During the recruitment period RV IgM (figure 2B) after 1–3 months (test specificity, 100%).
we used the semiautomated VIDAS Rubéole IgG Test version 1 One person who responded with low-avidity IgG (9.6%) but
(Vi1-G; bioMérieux, Marcy-l’Etoile, France), and results were re- had negative results with both IgM tests was arbitrarily consid-
ported as international units per milliliter. Anti-RV IgG concentra-
ered to have a primary response. Anti-RV IgG concentrations
tions from 20 to 40 IU/mL were interpreted as weak positive results.
measured by Vi2-G remained unchanged within 2 weeks afterFor final analysis, all available serum samples from vaccinated per-
rubella vaccination of 29 persons with primary immune re-sons were subjected to batchwise testing using the VIDAS Rubéole
sponses (P Å .16; paired means comparison).IgG Test version 2 (Vi2-G), in which IgG concentrations õ15 IU/
Secondary immune responses could be documented by highmL were interpreted as negative according to the manufacturer’s
recommendations. Both versions of this assay are based on the avidity of anti-RV IgG antibodies and negative specific IgM
indirect immunosorbent principle, with a solid phase coated by inac- responses after 1–3 months in 83 persons (figure 2). Nine
tivated wild virus antigen and alkaline phosphatase–conjugated subjects with secondary immune responses to rubella vaccina-
mouse monoclonal anti-human IgG antibodies and 4-methylum- tion by these criteria had prevaccination anti-RV antibody re-
belliferylphosphate as detecting reagents. In addition, anti-RV anti- sults below the cutoffs recommended by the manufacturers for
bodies were measured by Hämolyse-Gel-Test für Röteln (RHG; Vi2-G and/or RHG, and a response to rubella vaccination was
Labor Dr. Koch / Dr. Merk, Ochsenhausen, Germany). This test
not evident within 1–2 weeks (table 1; figure 1). After 1–2
is based on the complement-mediated lysis of RV hemagglutinin-
months, specific IgG concentrations increased ú10-fold in 5sensitized baby chick erythrocytes embedded in agarose gel that
and to a lesser degree in the rest of them. With a cutoff at 7has been penetrated by serum from punch holes. Hemolysis zone
mm for RHG, this test would be negative in only 2 personsdiameters of §9 mm (corresponding to 20 IU/mL by ELISA or
and yet remain 100% specific.1:32 by hemagglutination inhibition) were considered positive.
The avidity of anti-RV IgG was determined by the rubella IgG The sensitivities of Vi2-G and RHG were 90.4% and 97.6%,
avidity test (Labsystems, Helsinki), which applies the elution prin- respectively, in the selected group of 119 persons who could
ciple using a washing step with urea to an indirect solid-phase be tested appropriately for the type of immune response to
ELISA with alkaline phosphatase–conjugated anti-human IgG [31, rubella vaccination. If these results are representative of all
32]. Results were analyzed by using an Excel-based Macintosh 5060 persons tested during the study period, the sensitivity and
program that calculates the shift to the left of the dilution curves predictive value of negative Vi2-G results can be estimated at
caused by the elution step. Ç98.5% and 75%, respectively. The seroprevalence of anti-
Anti-RV IgM was detected by the AxSYM Rubella IgM assay
RV IgG in young Swiss adults is 96% [20]. Thus,Ç1% of them(Abbott Laboratories, Abbott Park, IL), an automated ELISA that
lack detectable RV antibodies despite previous immunization.uses microparticles coated with purified RV (strain HPV-77),
Anti-RV IgG concentrations increased slightly but sig-which bind on a glass fiber matrix after reaction with diluted serum,
nificantly within 2 weeks in 74 subjects with secondary re-and alkaline phosphatase–conjugated anti-human IgM with 4-
methylumbelliferylphosphate as detecting reagents; in this proce- sponses, from a mean value of 32.5 to 41.5 IU/mL (mean
dure, all sera were absorbed with the IMx rheumatoid factor neu- difference, 9 IU/mL; 95% confidence interval, 5 – 13 IU/mL;
tralization reagent according to the manufacturer’s instructions. P õ .001; paired means comparison) (figure 1A). A similar
As a second IgM test, we used the VIDAS Rubéole IgM Test response was evident with anti-RV antibody determinations
(bioMérieux), an automated m-capture ELISA with inactivated by RHG (P Å .75 and P Å .01 for primary and secondary
wild virus antigen and alkaline phosphatase–labeled Fab* frag-
responses, respectively; paired means comparisons) (figurements of a monoclonal anti–RV hemagglutinin antibody and 4-
1B). A clearcut increase in anti-RV IgG levels was evidentmethylumbelliferylphosphate for detection.
1 – 3 months after vaccination in persons with both primaryLow IgG avidity (õ15%) or intermediate IgG avidity (15%–
and secondary immune responses (median intervals, 34 and25%) and positive IgM test results 1–3 months after rubella vacci-
37 days, respectively), reaching similar mean (median) val-nation were classified as primary immune responses. High IgG
avidity and negative IgM results at this time interval were consid- ues of 112 (87) and 127 (105) IU/mL, respectively (tied P
ered to represent a secondary immune response; that is, these value Å .19; Mann-Whitney U test for difference between
persons must previously have been exposed to RV antigens. From groups at 1 – 3 months). Subjects with secondary immune
46 of 165 subjects, there were no adequately timed samples for responses and prevaccination anti-RV IgG concentrations of
the definite characterization of the type of the immune response õ15 IU/mL (n Å 8), 15– 29 IU/mL (n Å 30), and §30 IU/
by these techniques.
mL (n Å 43) showed a mean increase of 17.3-, 5.6-, and 3.4-Data were analyzed using the StatView 4.02 program (Abacus
fold, respectively (P õ .02 for all groups, unpaired meansConcepts, Berkeley, CA) for paired or unpaired means compari-
comparison) (figure 3A). Seventeen of the secondary re-sons, Mann-Whitney U tests, Wilcoxon signed rank tests, and box
sponses were õ2-fold. Mean IgG increases in primary im-plots. Statistical significance was defined as P õ .05.
mune responses were 58-fold. A similar evolution of the
Results responses was evident with RHG (figure 3B).
After a median observation interval of 152 days (range,Prevaccination anti-RV antibodies were negative by Vi2-G
(figure 1A) and RHG (figure 1B) in 35 subjects who developed 56 – 545), anti-RV IgG concentrations of 17 persons were
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Figure 1. A, Anti-RV IgG antibodies measured by ELISA before (Vi2-G-0) and 1–2 weeks (Vi2-G-1), 1–3 months (Vi2-G-2), or up to
median of 152 days (Vi2-G-3) after rubella vaccination in persons responding with IgM and low-avidity IgG antibodies 1–3 months after
vaccination (primary response, open boxes) compared with those producing no IgM and high-avidity IgG (secondary response, hatched boxes).
B, Similar presentation for anti-RV antibodies measured by radial hemolysis (RHG) before and after rubella vaccination. Box plots show
median and 50% of values within boxes and 90% within bars. Solid lines indicate cutoff values for positive results and equivocal range for
Vi2-G and RHG, respectively. Numbers in parentheses indicate how many samples were available for corresponding tests and subgroups.
rubella vaccination has a high protective efficacy, in particularbetween 27 and 150 IU/mL (median, 67 IU/mL). Eleven
for viremic infections [1, 2, 22, 28, 34]. However, in the ab-persons with prevaccination results §15 IU/mL had slightly
sence of wild virus exposure, protective vaccine-induced im-lower values than the 6 with negative prevaccination results
munity may wane [35, 36]. A few cases of reinfection during(medians, 66 and 74 IU/mL, respectively; P §.48, Mann-
pregnancy, with transmission of the virus to the fetus and theWhitney U test). This is also reflected in 11 of these 17
emergence of congenital rubella syndrome, have been de-subjects who could be grouped according to their immune
scribed in women with well-documented immune responses toresponse (figures 1A, 3).
vaccine or wild virus before conception [37, 38]. In spite of this,No vaccination side effects were reported.
any level of detectable antibody to RV is generally considered
presumptive evidence of protective immunity [1–3], especially
with tests that correlate with neutralizing antibodies [39, 40].Discussion
Although the presence of anti-RV antibodies detectable at any
Antibodies produced after exposure to wild type RV usually level does not completely rule out the possibility of viremic
infections by wild type RV and transmission to the fetus [37,confer lifelong protection from reinfection [17, 33]. Successful
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Figure 2. A, Avidity of anti-RV IgG anti-
bodies 1–3 months after rubella vaccination
in persons with primary or secondary immune
responses to vaccination. 2 serum samples with
equivocal results (between horizontal lines)
were anti-RV IgM–positive. B, Anti-RV IgM
responses before (IgM-0), and 1–2 weeks
(IgM-1), 1–3 months (IgM-2), or up to median
of 152 days (IgM-3) after rubella vaccination,
grouped according to type of immune response
to vaccine. Standardized index Å fluorescence
value of sample/fluorescence value of cutoff.
Values ú1 (horizontal line) are positive. For
explanation of box plots see legend to figure
1. Nos. of samples available for testing in dif-
ferent subgroups are shown in parentheses.
38], the demonstration of the lack of previous exposure and IgM response [11, 22, 23]. Reinfections by wild type virus,
however, have the potential to induce IgM antibodies, butimmune response to wild type or attenuated vaccine virus is
of preeminent importance. However, standardization of anti- usually at low levels [22, 44–46]. In our study, secondary
immune responses to rubella vaccination were unexpectedlyRV antibody concentrations for a variety of different techniques
is difficult to achieve, particularly at low levels [4, 8, 14]. This characterized by a quantitatively negligible, albeit statistically
significant, increase in anti-RV IgG concentrations within 2may jeopardize the recognition of susceptible persons who need
vaccination in order to curtail transmission of RV into and weeks and by peak levels after 1–3 months that were not
significantly higher than those in primary responders. Suchwithin the female population of childbearing age. We ap-
proached this problem by studying the immune response to delayed and attenuated secondary antibody responses have
previously been described in a few subjects after intranasalrubella vaccination.
The evolution of the avidity of anti-RV IgG and the produc- RV challenge [22, 46] or RV revaccination [21, 24]. As we
do not know the immunization history of most of our studytion of specific IgM antibodies within 3 months after rubella
vaccination clearly distinguished groups with primary and sec- participants, the potential contribution of the type of primary
immunization (by wild type or vaccine virus) to this sluggishondary immune responses. Primary immune responses evolved
as expected, with an IgM response and IgG antibodies of low secondary response remains undefined and will be impossible
to ascertain in a population with ongoing wild virus circula-avidity appearing within 4 weeks.
Secondary immune responses to vaccines are expected to tion [47, 48]. The presence of neutralizing antibodies in spite
of very low or undetectable antibody levels measured by othershow a rapid increase of IgG production [41–43] and no
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Table 1. False-negative or equivocal anti-RV antibodies in 9 female patients with secondary immune
responses to rubella vaccination characterized by high IgG avidity 1–3 months thereafter and negative
IgM tests throughout the observation period.
Before vaccination After vaccination
Interval Vi2-G RHG Interval Vi2-G RHG
Patient (days) (IU/mL) (mm) (days) (IU/mL) (mm) Comment
1 06 3 2 15 5 7 Pharyngitis
56 219 16
2 042 6 2 NA NA NA Pregnancy screening
48 120 13
3 0168 6 7 7 6 8 Pregnancy screening
35 24 11.5
4 0113 8 7 9 7 3 Pregnancy screening
41 32 10
5 02 9 8 7 13 8 NA
28 93 13
6 07 11 9 4 11 10 Pregnancy screening
36 45 12
7 0234 14 8.5 6 18 10.5 Pregnancy screening
41 26 9.5
8 028 14 9 4 12 10.5 Health care worker
32 294 15
9 011 15 8.5 5 12 9 210 IU/mL IgG after vaccination 15
30 367 13 years ago, pregnancy screening
NOTE. NA, not available. Vi2-G, VIDAS Rubéole IgG Test version 2; RHG, Hämolyse-Gel-Test für Röteln.
techniques [11] may inhibit the replication of vaccine virus After revaccination, rates of adverse reactions (particularly
joint-related complaints in females) have been lower than afterand thereby delay or abort the secondary immune response
[21, 22, 46] by preventing the production of sufficient amounts primary vaccination [53]. We therefore decline to withhold
vaccination from potentially susceptible persons and offerof immunogenic material. The inverse relation between the
increase of anti-RV IgG concentrations attained within 3 boosting to persons with low antibody levels. By the same
token, this approach avoids overestimating vaccine efficacy inmonths after vaccination and prevaccination values of IgG is
in agreement with this interpretation. population studies for the surveillance of mass vaccination
programs.Some persons fail to respond to repeated RV vaccinations
[40], and patients with congenital RV infection may be tolerant A well-calibrated ELISA for the detection of anti-RV IgG
has the potential to be as reliable as established techniquesto RV epitopes [40, 49–52]. In addition, antibody responses
to vaccination in previously immunized subjects tend to be such as radial hemolysis, which clearly separates susceptible
from immune subjects, even at a lower cutoff than the onetransient (this study and [11, 21, 22]). Therefore, boosting
previously immunized persons with low anti-RV antibody con- recommended by the manufacturer of RHG. The sequential use
of the two tests in case of a negative ELISA could reduce thecentrations may be ineffective, and additional vaccine doses
after childhood vaccination should mainly be targeted at the number of false-negative results and still provide the ease and
rapidity of an automated test for most cases. The results ob-unimmunized. In contrast, reinfection by wild type RV may
overcome the neutralizing capacity of antibodies and induce tained with the automated ELISA used in this study are not
necessarily transferable to other assays, even if they are basedantibody levels above those attainable by revaccination [28].
Both a modern automated ELISA and a radial hemolysis on similar test principles. Some recently developed automated
ELISAs for the detection and quantitation of anti-RV IgG maytest for the determination of rubella immunity had excellent
specificity in identifying persons who have previously mounted give rise to false-positive results in a large proportion of sub-
jects mounting a primary immune response to vaccination, par-an immune response to RV. Thus, the cutoffs recommended
for these tests avoid false-positive results and ensure that vacci- ticularly when using a cutoff value below 15 IU/mL (data not
shown). Therefore, for low levels of antibodies, the correctnation can be targeted at all susceptible persons, especially if
the indication to vaccinate is extended into a safety margin of calibration of every assay should be ascertained using serum
panels that have been characterized according to biologic crite-weakly positive results (e.g., up to 25 IU/mL). Lowering the
cutoff value would compromise specificity, yet it would im- ria instead of relying exclusively on standard serum prepara-
tions. In defining the cutoff values, priority should be given toprove the predictive value of positive results only slightly, as
the majority of false-negative results could not be avoided. the avoidance of false-positive results.
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Figure 3. A, Mean values and 95% con-
fidence intervals of anti-RV IgG concentra-
tions before and 1–3 months and ú2
months after rubella vaccination. Results
are grouped by primary and secondary im-
mune responses and by prevaccination anti-
RV IgG concentrations (Vi2-G-0). l, pri-
mary immune responses (n Å 36); h,
secondary immune responses, Vi2-G-0
õ15 IU/mL (n Å 8); n, secondary immune
responses, Vi2-G-0 15–29 IU/mL (nÅ 30);
L, secondary immune responses, Vi2-G-0
§30 IU/mL (n Å 43). B, Similar presenta-
tion for radial hemolysis (RHG), grouped
by primary and secondary immune re-
sponses and by prevaccination results
(RHG-0). l, primary immune responses (n
Å 34); h, secondary immune responses,
RHG-0 õ7 mm (n Å 2); n, secondary im-
mune responses, RHG-0 7 to õ9 mm (n Å
5); L, secondary immune responses, RHG-
0 §9 mm (n Å 73).
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